Skip to main content
Icure Pharmaceutical Incorporation logo

Icure Pharmaceutical Incorporation — Investor Relations & Filings

Ticker · 175250 ISIN · KR7175250000 KO Manufacturing
Open in API
Filings indexed 321 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country KR South Korea
Listing KO 175250

About Icure Pharmaceutical Incorporation

https://www.icure.co.kr/eng/

Icure Pharmaceutical Incorporation is a biopharmaceutical company that researches, develops, manufactures, and commercializes high-tech drug products. The company's core expertise lies in its Transdermal Drug Delivery System (TDDS) technology, which facilitates 'Cure & Care' solutions through the skin. Its portfolio includes both pharmaceutical products, such as NSAIDS patches, and cosmetic lines developed with a pharmaceutical and medical foundation. Icure focuses on creating innovative formulations and drug delivery systems to improve therapeutic outcomes and patient convenience.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획자진취하등) (도네페질패취의 미국 FDA 제1상 임상시험계획 자진취하)
Regulatory Filings Classification · 80% confidence The document is a Korean regulatory disclosure titled “투자판단 관련 주요경영사항” concerning the voluntary withdrawal of a clinical trial application. It is a standalone announcement of a material event rather than a full report, financial statement, or presentation. It does not fit any specific category like board changes, financing updates, or financial reports. Under the fallback / general regulatory announcements category, it best matches “Regulatory Filings (RNS).”
2026-05-22 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 93% confidence The document is titled “분기보고서” (Quarterly Report) for the period 2026.01.01–2026.03.31 (제27기) and includes full financial statements, business overviews, capital changes, risk management, and other substantive data. It is a comprehensive interim report rather than an announcement or certification. Therefore it should be classified as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
[기재정정]분기보고서 (2026.03)
Interim / Quarterly Report Classification · 94% confidence The document is labeled as a “분기보고서” (quarterly report) covering the period 2026.01.01–2026.03.31, and contains full financial statements (summary financials, business description, segment information, statements of changes in equity, balance sheet items, etc.). Although it begins with an amendment notice for the originally filed quarterly report, the body presents the complete interim report itself with substantive financial data, fitting the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
[기재정정]사업보고서 (2025.12)
Regulatory Filings
2026-05-07 Korean
[기재정정]사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the company 'Icure Pharmaceutical' (아이큐어 주식회사). It contains detailed financial data, management discussions, corporate governance information, and operational details for the fiscal year ending December 31, 2025. It is a comprehensive annual filing submitted to the Financial Services Commission and Korea Exchange. Although it is labeled as a 'correction' (정정신고), it constitutes the full annual report filing, not merely an announcement of one. FY 2025
2026-04-20 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 95% confidence The document is a standalone auditor’s report (“감사보고서”) issued by an external audit firm on the consolidated financial statements of 아이큐어주식회사 for the year ended December 31, 2025. It contains the auditor’s opinion, basis of opinion, key audit matters, and the full set of audited consolidated financial statements with notes. This matches the definition of an Audit Report / Information (AR), not an Annual Report or a simple announcement. FY 2025
2026-04-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.